


Amendments to the Claims:

This listing will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (currently amended) A compound according to formula I :



(I)

wherein:

R^1 and R^3 are each independently H, lower alkyl, $-SO_3H$, or $-PO_3H_2$;

R^2 is selected from hydrogen, $-SO_3H$ or $-PO_3H$

or R^1 and R^2 together with the atoms to which they are bound form a methylenedioxy group ;

or R^2 and R^3 together with the atoms to which they are bound form a methylenedioxy group; and

X^1 is bound in the 2- or 3- position and is of the formula:

$Ar-X^3$ wherein

Ar is furanyl, thienyl, pyridyl, cyclohexyl or benzyl and X^3 is a substituent on the ortho, meta, or para position of the phenyl ring and is H, C, N, NR' , $NR'R''$, $NR'SO_2R''$, or O; wherein R' and R'' are each independently H, or lower alkyl ; and OR^1 is $O(CH_2)_nY$, wherein n is 1 to 2, Y is OR^4 , NR^5R^6 , $COOR^4$, or $CONR^5R^6$; or $O[CH_2CH(OH)CH_2]Y$, wherein Y is H, OR^4 , NR^5R^6 , $COOR^4$, or $CONR^5R^6$; wherein T is Y or $[CH_2CH(OH)CH_2]Y$, Y is H, OR^4 , NR^5R^6 , $COOR^4$, or $CONR^5R^6$ wherein R^4 , R^5 , and R^6 are each independently H, or lower alkyl, and R^5 and R^6 together may form a 5 to 7-membered ring; or pharmaceutically acceptable salts thereof, subject to the proviso that the compound according to formula I is not baicalein or 5, 6, 7-trihydroxyisoflavone or a compound wherein X^3 is hydroxyl-substituted phenyl.

2. (Cancelled)

3. (Cancelled)

4. (Original) The compound according to claim 1, wherein R¹, R² and R³ are each independently-SO₃H or-PO₃H₂.

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Previously Presented) The compound wherein the compound is 4'-(N,N-dimethylamino)-5, 6,7-trimethoxyflavone, 4'-(methylamino)-5, 6,7- trimethoxyflavone, 4'-[N-methyl-N-(3-methoxypropyl)amino]-5,6,7-trimethoxyflavone, 4'-[N,N-di-(2-hydroxyethyl)-amino]-5,7-dihydroxy-6-methoxyflavone, 4'-(2-hydroxyethylamino)-5,7-dihydroxy-6-methoxyflavone, 4'-(2-methanesulfonatoethylamino)-5,7-dihydroxy-6-methoxyflavone, 4'-[2-(N,N-diethylamino)ethylamino]-5,7-dihydroxy-6-methoxyflavone, 2,3-diphenyl-5,6,7-trimethoxychromone, 2,3-diphenyl-5,6,7-trihydroxychromone, 4'-(methylsulfonamido)-5,6,7-trimethoxyflavone, 4'-[2-(N,N-diethylamino)ethoxy]-6,7-methylenedioxy-5-hydroxy-flavone, 4'-(2,3-dihydroxy-propyloxy)-5,6,7-trimethoxyflavone, or 4'-(Carbomethoxymethoxy)-5,6,7-trimethoxyflavone.

12. (Original) A pharmaceutical formulation comprising a compound according to claim 1 and at least one pharmaceutically acceptable carrier, diluent, or excipient.

13. (Original) The pharmaceutical formulation comprising a compound according to

claim 12, wherein the pharmaceutically acceptable carrier is an aqueous carrier.

14. (Currently amended) A method of treating diseases associated with overproduction of TNF- α selected from the group consisting of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ~~organ failure, and pulmonary fibrosis~~, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (currently amended) A method of treating liver damage, lung damage or kidney damage or combinations thereof resulting from over production of TNF- α or superoxide anion radicals comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

19. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)


27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (currently amended) A method of treating conditions selected from the group consisting of diseases associated with the overproduction of TNF- α , overproduction of superoxide anion radical, ~~liver damage, lung damage, kidney~~ and combinations thereof, comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula V:



wherein: R^7 , R^8 , and R^9 are each independently H, lower alkyl, $-SO_3H$, $-PO_3H_2$; or R^7 and R^8 together with the atoms to which they are bound form a methylenedioxy group or

R^8 and R^9 together with the atoms to which they are bound form a methylenedioxy group ;

X^1 is a substituent on the ortho, meta, or para position of the phenyl ring and is H, C, NH_2 , $NHCOCH_3$, or OR^{10} , wherein R^{10} is H, lower alkyl, or pharmaceutically acceptable salts thereof.

32. (Cancelled)

33 (Cancelled)

34. (Cancelled)

35. (Cancelled)

36. (Cancelled)

37. (Cancelled)

38. (Cancelled)

39. (previously presented) The method according to claim 31, wherein the compound is 5,6,7- trihydroxyisoflavone, 4',5,6,7- tetrahydroxyflavone, or 4'-amino -5,7-dihydroxy-6-methoxy flavone.

40. (Cancelled)

41. (Cancelled)

42. (Cancelled)

43. (Cancelled)

44. (previously presented) The method according to claim 31, wherein the pharmaceutical composition is administered in combination with at least one other therapeutic agent useful for the prevention or treatment of conditions associated with overproduction of TNF- α , and liver damage, lung damage or kidney damage .

45. (Original) The method according to claim 31, wherein the pharmaceutical composition is administered orally or parenterally.

46. (previously presented) A method of treating conditions selected from the group consisting of diseases associated with the overproduction of TNF- α ~~and liver damage, lung damage or kidney damage~~ and combinations thereof, comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of baicalein-6-sulfate, baicalein-6,7-disulfate, baicalein-6-phosphate, baicalein-6,7-diphosphate, baicalein- 5,6, 7-triphosphate, sodium and potassium salt derivatives thereof, and pharmaceutically acceptable salts thereof.

47. (Cancelled)

48. (Cancelled)

49 (Cancelled)

50 (Cancelled)

51. (Cancelled)

52. (previously presented) The method according to claim 46, wherein the pharmaceutical composition is administered in combination with at least one other therapeutic agent useful for the prevention or treatment of conditions associated with overproduction of TNF- α .

53. (Original) The method according to claim 44, wherein the pharmaceutical composition is administered orally or parentally.

54. (previously presented) A method of treating conditions selected from the group consisting of diseases associated with the overproduction of TNF- α , ~~and liver damage, lung damage or kidney damage~~ and combinations thereof, comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of compound as in Claim 11.

55. (Cancelled)


56. (Cancelled)

57. (Cancelled)

58. (Cancelled)

59. (Cancelled)

60 (previously presented) A method of treating liver damage, lung damage or kidney damage resulting from over production of TNF- α or superoxide anion radicals which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the formula:



wherein R_1 is selected from hydrogen and alkyl;

R_2 is selected from hydrogen, lower alkyl and sulfate or R_1 and R_2 together with the atoms to which they are joined jointly form a methylene dioxy group;

R_3 is selected from hydrogen, lower alkyl and sulfate;

X_1 is selected from hydrogen, phenyl and substituted phenyl wherein the substituent is hydroxyl, alkoxy, amino, mono or dialkyl substituted amino, hydroxyl alkoxy, or aminoalkoxy

and X_2 is selected from hydrogen and phenyl, and X_1 and X_2 can not both phenyl.